Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: Results of a naturalistic clinical trial

Dennis A. Revicki, Robert M A Hirschfeld, Eileen P. Ahearn, Richard H. Weisler, Cynthia Palmer, Paul E. Keck

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: The clinical, quality of life (QOL), and medical cost outcomes of treatment with divalproex were compared with lithium in patients with bipolar I disorder over 1 year. Methods: In a pragmatic, randomized clinical trial, 201 adults hospitalized with bipolar I manic or mixed episodes were randomized to divalproex or lithium, in addition to usual psychiatric care, and followed for 1 year. All subsequent treatment of bipolar disorder was managed by the patient's psychiatrist. Symptoms of mania and depression were evaluated at baseline and at hospital discharge. Assessments at the start of maintenance therapy and after 1, 3, 6, 9 and 12 months included manic and depressive symptoms, disability days and QOL. Medical resource use data were also collected monthly and costs were estimated using national sources. Results: Divalproex-treated patients (12%) were less likely to discontinue study medications for lack of efficacy or adverse effects than lithium-treated patients (23%). No statistically significant differences between the treatment groups were observed over the 1-year maintenance phase for clinical symptoms, QOL outcomes, or disability days. Mean estimated total medical costs were $28,911 for the divalproex group compared with $30,666 for the lithium treatment group. Patients continuing mood stabilizer therapy at 3 months had slightly better health outcomes and substantially lower total medical costs than those who discontinued therapy ($10,091 versus $34,432, respectively). Conclusions: Divalproex maintenance treatment for bipolar disorder resulted in comparable medical costs, clinical and QOL outcomes compared with lithium. Patients remaining on mood stabilizer therapy had substantially lower total medical costs and better health outcomes compared with those who discontinued therapy.

Original languageEnglish (US)
Pages (from-to)183-193
Number of pages11
JournalJournal of Affective Disorders
Volume86
Issue number2-3
DOIs
StatePublished - Jun 2005

Fingerprint

Valproic Acid
Bipolar Disorder
Lithium
Cost-Benefit Analysis
Clinical Trials
Quality of Life
Costs and Cost Analysis
Therapeutics
Health Care Costs
Psychiatry
Pragmatic Clinical Trials
Depression
Randomized Controlled Trials
Maintenance
Health

Keywords

  • Bipolar disorder
  • Clinical trials
  • Cost-effectiveness analysis
  • Divalproex
  • Lithium

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder : Results of a naturalistic clinical trial. / Revicki, Dennis A.; Hirschfeld, Robert M A; Ahearn, Eileen P.; Weisler, Richard H.; Palmer, Cynthia; Keck, Paul E.

In: Journal of Affective Disorders, Vol. 86, No. 2-3, 06.2005, p. 183-193.

Research output: Contribution to journalArticle

Revicki, Dennis A. ; Hirschfeld, Robert M A ; Ahearn, Eileen P. ; Weisler, Richard H. ; Palmer, Cynthia ; Keck, Paul E. / Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder : Results of a naturalistic clinical trial. In: Journal of Affective Disorders. 2005 ; Vol. 86, No. 2-3. pp. 183-193.
@article{bb8b28fca0f14312af2a2406d2e3748f,
title = "Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: Results of a naturalistic clinical trial",
abstract = "Objective: The clinical, quality of life (QOL), and medical cost outcomes of treatment with divalproex were compared with lithium in patients with bipolar I disorder over 1 year. Methods: In a pragmatic, randomized clinical trial, 201 adults hospitalized with bipolar I manic or mixed episodes were randomized to divalproex or lithium, in addition to usual psychiatric care, and followed for 1 year. All subsequent treatment of bipolar disorder was managed by the patient's psychiatrist. Symptoms of mania and depression were evaluated at baseline and at hospital discharge. Assessments at the start of maintenance therapy and after 1, 3, 6, 9 and 12 months included manic and depressive symptoms, disability days and QOL. Medical resource use data were also collected monthly and costs were estimated using national sources. Results: Divalproex-treated patients (12{\%}) were less likely to discontinue study medications for lack of efficacy or adverse effects than lithium-treated patients (23{\%}). No statistically significant differences between the treatment groups were observed over the 1-year maintenance phase for clinical symptoms, QOL outcomes, or disability days. Mean estimated total medical costs were $28,911 for the divalproex group compared with $30,666 for the lithium treatment group. Patients continuing mood stabilizer therapy at 3 months had slightly better health outcomes and substantially lower total medical costs than those who discontinued therapy ($10,091 versus $34,432, respectively). Conclusions: Divalproex maintenance treatment for bipolar disorder resulted in comparable medical costs, clinical and QOL outcomes compared with lithium. Patients remaining on mood stabilizer therapy had substantially lower total medical costs and better health outcomes compared with those who discontinued therapy.",
keywords = "Bipolar disorder, Clinical trials, Cost-effectiveness analysis, Divalproex, Lithium",
author = "Revicki, {Dennis A.} and Hirschfeld, {Robert M A} and Ahearn, {Eileen P.} and Weisler, {Richard H.} and Cynthia Palmer and Keck, {Paul E.}",
year = "2005",
month = "6",
doi = "10.1016/j.jad.2005.01.002",
language = "English (US)",
volume = "86",
pages = "183--193",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder

T2 - Results of a naturalistic clinical trial

AU - Revicki, Dennis A.

AU - Hirschfeld, Robert M A

AU - Ahearn, Eileen P.

AU - Weisler, Richard H.

AU - Palmer, Cynthia

AU - Keck, Paul E.

PY - 2005/6

Y1 - 2005/6

N2 - Objective: The clinical, quality of life (QOL), and medical cost outcomes of treatment with divalproex were compared with lithium in patients with bipolar I disorder over 1 year. Methods: In a pragmatic, randomized clinical trial, 201 adults hospitalized with bipolar I manic or mixed episodes were randomized to divalproex or lithium, in addition to usual psychiatric care, and followed for 1 year. All subsequent treatment of bipolar disorder was managed by the patient's psychiatrist. Symptoms of mania and depression were evaluated at baseline and at hospital discharge. Assessments at the start of maintenance therapy and after 1, 3, 6, 9 and 12 months included manic and depressive symptoms, disability days and QOL. Medical resource use data were also collected monthly and costs were estimated using national sources. Results: Divalproex-treated patients (12%) were less likely to discontinue study medications for lack of efficacy or adverse effects than lithium-treated patients (23%). No statistically significant differences between the treatment groups were observed over the 1-year maintenance phase for clinical symptoms, QOL outcomes, or disability days. Mean estimated total medical costs were $28,911 for the divalproex group compared with $30,666 for the lithium treatment group. Patients continuing mood stabilizer therapy at 3 months had slightly better health outcomes and substantially lower total medical costs than those who discontinued therapy ($10,091 versus $34,432, respectively). Conclusions: Divalproex maintenance treatment for bipolar disorder resulted in comparable medical costs, clinical and QOL outcomes compared with lithium. Patients remaining on mood stabilizer therapy had substantially lower total medical costs and better health outcomes compared with those who discontinued therapy.

AB - Objective: The clinical, quality of life (QOL), and medical cost outcomes of treatment with divalproex were compared with lithium in patients with bipolar I disorder over 1 year. Methods: In a pragmatic, randomized clinical trial, 201 adults hospitalized with bipolar I manic or mixed episodes were randomized to divalproex or lithium, in addition to usual psychiatric care, and followed for 1 year. All subsequent treatment of bipolar disorder was managed by the patient's psychiatrist. Symptoms of mania and depression were evaluated at baseline and at hospital discharge. Assessments at the start of maintenance therapy and after 1, 3, 6, 9 and 12 months included manic and depressive symptoms, disability days and QOL. Medical resource use data were also collected monthly and costs were estimated using national sources. Results: Divalproex-treated patients (12%) were less likely to discontinue study medications for lack of efficacy or adverse effects than lithium-treated patients (23%). No statistically significant differences between the treatment groups were observed over the 1-year maintenance phase for clinical symptoms, QOL outcomes, or disability days. Mean estimated total medical costs were $28,911 for the divalproex group compared with $30,666 for the lithium treatment group. Patients continuing mood stabilizer therapy at 3 months had slightly better health outcomes and substantially lower total medical costs than those who discontinued therapy ($10,091 versus $34,432, respectively). Conclusions: Divalproex maintenance treatment for bipolar disorder resulted in comparable medical costs, clinical and QOL outcomes compared with lithium. Patients remaining on mood stabilizer therapy had substantially lower total medical costs and better health outcomes compared with those who discontinued therapy.

KW - Bipolar disorder

KW - Clinical trials

KW - Cost-effectiveness analysis

KW - Divalproex

KW - Lithium

UR - http://www.scopus.com/inward/record.url?scp=20344380905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344380905&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2005.01.002

DO - 10.1016/j.jad.2005.01.002

M3 - Article

C2 - 15935238

AN - SCOPUS:20344380905

VL - 86

SP - 183

EP - 193

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 2-3

ER -